Fig. 5
From: KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
MRTX1257 increases the anti-proliferative effect of RT in CT26 KRASG12C+/+ tumors but not in CT26 WT tumors. A BALB/c mice were subcutaneously inoculated with CT26 WT cells or CT26 KRASG12C+/+ cells. Once the tumors reached an average volume of 90–100 mm3, mice received via oral administration 50 mg/kg of MRTX1257 or vehicle. The day after, mice received a single fraction of 6 Gy on the tumor mass. MRTX1257 at the dose of 50 mg/kg or vehicle were then administered at D1 and D3 after RT. At D4 after RT, mice were sacrificed, tumors were harvested and then fixated using paraformaldehyde (PFA) 4%. Immunohistochemistry for Ki67 and then the quantification of Ki67+ cells were performed. B Photographs at magnification 13X of 4 µm-thick CT26 KRASG12C+/+ (left) or CT26 WT (right) tumor slices stained with anti-Ki67 antibody. Two representative photographs, each of them from a different tumor, are represented for each condition. C Quantification of Ki67+ cells per mm2 in CT26 KRAS G12C+/+ tumor slices. Each point is representative of a single tumor. Mean ± standard-errors to mean (SEM). N = 3–5 tumors/group. *: p < 0.05; **: p < 0.01 (one-way ANOVA). D Quantification of Ki67+ cells per mm.2 in CT26 WT tumor slices. Each point is representative of a single tumor. Mean ± standard-errors to mean (SEM). n = 3 tumors/group. *: p < 0.05 (one-way ANOVA)